PRMT5 Inhibition Modulates E2F1 Methylation and Gene-Regulatory Networks Leading to Therapeutic Efficacy in JAK2V617F-Mutant MPN
Open Access
- 14 July 2020
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 10 (11), 1742-1757
- https://doi.org/10.1158/2159-8290.CD-20-0026
Abstract
We investigated the role of PRMT5 in myeloproliferative neoplasm (MPN) pathogenesis and aimed to elucidate key PRMTS targets contributing to MPN maintenance. PRMTS is overexpressed in primary MPN cells, and PRMT5 inhibition potently reduced MPN cell proliferation ex vivo. PRMT5 inhibition was efficacious at reversing elevated hematocrit, leukocytosis, and splenomegaly in a model of JAK2(V)(617)(F+) polycythemia vera and leukocyte and platelet counts, hepatosplenomegaly, and fibrosis in the MPLW515L model of myelofibrosis. Dual targeting of JAK and PRMT5 was superior to JAK or PRMTS inhibitor monotherapy, further decreasing elevated counts and extramedullary hematopoiesis in vivo. PRMT5 inhibition reduced expression of E2F targets and altered the methylation status of E2F1 leading to attenuated DNA damage repair, cell-cycle arrest, and increased apoptosis. Our data link PRMTS to E2F1 regulatory function and MPN cell survival and provide a strong mechanistic rationale for clinical trials of PRMT5 inhibitors in MPN. SIGNIFICANCE: Expression of PRMT5 and E2F targets is increased in JAK2(V)(617)(F+) MPN. Pharmacologic inhibition of PRMT5 alters the methylation status of E2F1 and shows efficacy in JAK2(V)(617)(F)/MPLW515L MPN models and primary samples. PRMT5 represents a potential novel therapeutic target for MPN, which is now being clinically evaluated.Other Versions
Funding Information
- German Research Foundation (PA 2541/1-1)
- NIH (P30 CA008748)
- National Cancer Institute (R35 CA197594-01A1)
- National Cancer Institute (P01 CA108671)
- Damon Runyon Cancer Research Foundation (DRG 22-17)
- National Cancer Institute (K99 CA248460)
- German Research Foundation (PA 2541/1-1)
This publication has 47 references indexed in Scilit:
- Arginine methylation controls growth regulation by E2F-1The EMBO Journal, 2012
- A novel murine model of myeloproliferative disorders generated by overexpression of the transcription factor NF-E2The Journal of Experimental Medicine, 2012
- Versatility of PRMT5-induced methylation in growth control and developmentTrends in Biochemical Sciences, 2011
- TNFα facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasmsBlood, 2011
- Prmt5 is essential for early mouse development and acts in the cytoplasm to maintain ES cell pluripotencyGenes & Development, 2010
- Physiological Jak2V617F Expression Causes a Lethal Myeloproliferative Neoplasm with Differential Effects on Hematopoietic Stem and Progenitor CellsCancer Cell, 2010
- Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosisBlood, 2010
- Mutation in TET2 in Myeloid CancersThe New England Journal of Medicine, 2009
- Protein Arginine Methylation in Mammals: Who, What, and WhyMolecular Cell, 2009
- A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia veraNature, 2005